Abstract

METHOD DEVELOPMENT AND VALIDATION OF OXALIPLATIN BY RP-HPLC

Mayur A. Murkar* and Narendra Gowekar

ABSTRACT

Oxaliplatin therapy is Associated with a low rate of transient serum aminotransferase elevations, but is commonly associated with sinusoidal and vascular injury to the liver which can lead Sinusoidal obstruction syndrome and to nodular regenerative hyperplasia with Noncirrhotic portal hypertension. Oxaliplatin is anintravenously administered platinum containing alkylating agent Which is used for the treatment of advanced colorectal cancer. Molecular formula: C8H14N2O4Pt Molecular weight: 397.29g/mol Chemical name: [(1R,2R)-2-azanidylcyclohexyl] azanide; oxaliacid ; platinum(2+) Description: White crystals powder Category: Anti-neoplastic Agents MECHANISM OF ACTION The compound features a square planar platinum(II) center. In contrast to other Drugs of the platinum-based antineoplastic class of drugs cisplatin and carboplatin, Oxaliplatin features the bidentate ligand trans-1,2-diaminocyclohexane in place of the Two monodentate ammine ligands. It also features a bidentate oxalate group. The three-dimensional structure of the molecule has been elucidated by X-ray crystallography, although the presence of pseudosymmetry in the crystal structure Has caused confusion in its interpretation.

Keywords: Anticancer drug, oxaliplatin, RP-HPLC, colorectal cancer.